Cross-sectional study assessing long-term safety of interferon-β-1b for relapsing-remitting MS

Neurology

Volumn 74, Issue 23, 2010, Pages 1877-1885

  Reder, A T ^a   Ebers, G C ^b   Traboulsee, A ^c   Li, D ^c   Langdon, D ^d   Goodin, D S ^e   Bogumil, T ^f   Beckmann, K ^g   Konieczny, A ^g  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BAYER CORPORATION   (United States)

^g BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NEUTRALIZING ANTIBODY; PLACEBO; PREDNISONE; PROTEIN A;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ATTRIBUTABLE RISK; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DROWNING; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FAILURE; LONG TERM CARE; LUNG CANCER; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PANCREAS CANCER; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SKIN NECROSIS; THYROID DISEASE; TREATMENT DURATION;

EID: 77953353229     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181e240d0     Document Type: Article

References (24)

1. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study: I: clinical course and disability. Brain 1989;112:133-146. (Pubitemid 19056478)
2. Yoshida EM, Rasmussen SL, Steinbrecher UP, et al. Fulminant liver failure during interferon beta treatment of multiple sclerosis. Neurology 2001;56:1416.
3. Tremlett HL, Oger J. Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes. Mult Scler 2004;10:298-301.
4. Durelli L, Oggero A, Verdun E, et al. Thyroid function and anti-thyroid antibodies in MS patients screened for interferon treatment: a multicenter study. J Neurol Sci 2001;193:17-22.
5. Polman CH, Kappos L, Dahlke F, et al. Interferon beta-1b treatment does not induce autoantibodies. Neurology 2005;64:996-1000.
6. Durelli L, Ferrero B, Oggero A, et al. Thyroid function and autoimmunity during interferon-/3-1b treatment: a multicenter prospective study. J Clin Endocrinol Metab 2001;86:3525-3532. (Pubitemid 32755939)
7. The IFN-B Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-661.
8. The IFN-B Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
9. Ebers GC, Reder AT, Traboulsee A, et al. Long-term follow-up of the original interferon-/3-1b trial in multiple sclerosis: design and lessons from 16-year observational study. Clin Ther 2009;31:1724-1736.
10. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial: UBC MS/MRI Study Group and IFN-B Multiple Sclerosis Study Group. Neurology 1993;43:662-667.
11. Petkau AJ, White RA, Ebers GC, et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004;10:126-138.
12. EuroQoL Group. EuroQoL: a new facility for the management of health-related quality of life. Health Policy 1990; 16:199-208.
13. Kremenchutzky M, Cottrell D, Rice G, et al. The natural history of multiple sclerosis: a geographically based study 7: progressive-relapsing and relapsing-progressive multiple sclerosis: are-evaluation. Brain 1999;122:1941-1949. (Pubitemid 29473865)
14. Rice GP, Ebers GC, Lublin FD, Knobler RL. Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. Neurology 1999;52:1893-1895.
15. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-1249.
16. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68:977-984. (Pubitemid 46569129)
17. Sorensen PS, Deisenhammer R, Duda P, et al. Guidelines on use of anti-IFN-/3 antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-/3 antibodies in multiple sclerosis. Eur J Neurol 2005;12:817-827.
18. Files JG, Hargrove D, Delute L, Cantillon M. Measured neutralizing titers of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay. J Interferon Cytokine Res 2007;27:637-642
19. The IFN-B Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894.
20. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999;52:1277-1279.
21. Rice GP, Nicolle E, Lesaux J, Ebers GC, Kremenchutzky M, Karlik S. Long term safety, compliance and evolution of neutralizing antibodies in MS patients treated with in-terferon beta 1B. Mult Scler 2001;7(suppl 1):S54.
22. Midgard R, Albrektsen G, Riise T, Kvåle G, Nyland H. Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in Møre and Romsdal, Norway. J Neurol Neurosurg Psychiatry 1995;58:417-421.
23. Minden SL, Schiffer RB. Affective disorders in multiple sclerosis. Review and recommendations for clinical research Arch Neurol 1990;47:98-104.
24. Goodin D, Jones J, Ebers G, et al. The interferon beta-1b 16-year long-term follow-up study: measuring efficacy after controlling for bias in long-term follow-up. Neurology 2009;72(11, suppl 3):P05.131, A237. Abstract.